# Edgar Filing: ARRAY BIOPHARMA INC - Form 4

### ARRAY BIOPHARMA INC

Form 4

November 22, 2002

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

#### FORM 4

Washington, D.C. 20549

#### OMB APPROVAL

o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response .... 0.5

(Print or Type Responses) 1. Name and Address of Reporting Person\* Relationship of Reporting Person(s) to Issuer Issuer Name and Ticker or Trading Symbol (Check all applicable) ARRAY BIOPHARMA INC./ARRY **SNITMAN DAVID** L X Director 10% Owner X Officer (Last) (First) (Middle) I.R.S. Identification 4. Statement for Other Number of Month/Day/Year (give title (specify below) Reporting Person, if below) an entity (voluntary) CHIEF OPERATING OFFICER, VICE 3200 WALNUT STREET 11/21/02 PRESIDENT, BUSINESS DEVELOPMENT If Amendment, Date 7. Individual or Joint/Group Filing (Street) (Check Applicable Line) of Original (Month/Day/Year) X Form filed by One Reporting Person Form filed by More than 80301 BOULDER CO One Reporting Person (City) (State) (Zip) Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of 2. Transaction Deemed 3. Transaction 4. Securities Acquired (A) 5. Amount of 6. Ownership 7. Nature of 2A. Execution Date, or Disposed of (D) Securities Indirect Security Date Code Form: (Instr. 3, 4 and 5) Beneficially Direct (D) Beneficial (Instr. 3) if any (Instr. 8) Owned or Indirect Ownership Following (Instr. 4) (T) Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) (Month/Day/Year) (Month/Day/Year) Code V Amount (A) Price or (D) 11/21/02 COMMON 11/21/02 S(1)5,000 D \$8.50 1,354,011 D STOCK 100,000 Ι (2)

# Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ORM 4 (Continued)			Table II (e	Derivative e.g., puts, o	e Securi calls, wa	ties Aco rrants	quired, , option	Dispos s, conv	ed o	of, or l ble se	Beneficiall curities)	y O	wned		
Derivative Constitution (Instr. 3)	Conversion 3. Tran or Exercise (More Price of Derivative Security	Transaction (Month/Day,		Deemed Date, if a (Month/I	any		. Transaction Code (Instr. 8)			Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Date Exercisable and Expiration Date (Month/Day/Year)		
							Code	V		(A)	(D)		Date Exercisal	ole	Expiration Date
. Title and Amount of Securities (Instr. 3 and 4)	Underlying	8.	Price of De Security (Instr. 5)	rivative	D Se Be Fe Ti	umber of erivative curities eneficial ollowing ransactinstr. 4)	re s ally Owr g Repor	ned ted	10	Deri Secu	nership For vative urities: Dir or Indirect ir. 4)	ect		Bene	ership
Title	Amount or Number of Shares	er													

	Edgar Filing: ARRAY BIOPHARMA INC	C - Form 4					
Explanation of	of Responses:						
(1) TI	he sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopt	ed by the reporting person on September 30, 2002.					
(2) Ti	nese shares are held in trust for the benefit of the reporting person's children.						
	/s/ DAVID L. SNITMAN	November 22, 2002					
	**Signature of Reporting Person	Date					
Reminder:	Report on a separate line for each class of securities beneficially owned directly or indirectly	ctly.					
*	* If the form is filed by more than one reporting person, <i>see</i> Instruction 4(b)(v).						
**	** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).						
Note: http://www.se Last update:	ec.gov/divisions/corpfin/forms/form4.htm	ient, see Instruction 6 for procedure.					